SAB Biotherapeutics (SABS) Common Equity (2020 - 2026)
SAB Biotherapeutics (SABS) reported Common Equity of $214.79 million for Q2 2026, compared with $12.02 million a year earlier and down 5.5% from the prior quarter.
Powered by 
Analysis
SAB Biotherapeutics (SABS) Common Equity (2020 - 2026) Analysis & Trends
At the end of FY2025, SAB Biotherapeutics posted Common Equity of $151.5 million, up 483.3% from FY2024.
- Common Equity has a five-year compound annual growth rate of 31.2% (FY2020 to FY2025).
- By year, Common Equity came in at $25.97 million in FY2024 (-54.7%), $57.3 million in FY2023 (+84.5%), $31.06 million in FY2022 (-19.4%) and $38.55 million in FY2021 (-1.2%).
- Five-year quarterly Common Equity spans a low of $12.02 million in Q2 2025 and a high of $227.25 million in Q1 2026.
- Year over year, Common Equity gained in four of the last seven quarters, with growth averaging 249.4%.
- The high point for year-over-year Common Equity in five years was Q1 2026 (growth of 961.5%); the low point was Q2 2025 (a decline of 73.9%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $227.25 million (Q1 2026), $151.5 million (Q4 2025) and $165.07 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,133.90 Bn | 1,102.48 Bn | 19.71 Bn | 33.88 Bn |
| 2 | Johnson & Johnson | 616.46 Bn | 534.99 Bn | 17.26 Bn | 84.97 Bn |
| 3 | AbbVie | 501.26 Bn | 474.37 Bn | 12.70 Bn | -5.94 Bn |
| 4 | Merck | 367.00 Bn | 321.38 Bn | 12.21 Bn | 41.98 Bn |
| 5 | Novartis Ag | 297.91 Bn | 261.90 Bn | 11.24 Bn | 41.95 Bn |
| 6 | Astrazeneca | 261.33 Bn | 235.02 Bn | 12.86 Bn | 50.37 Bn |
| 7 | Amgen | 235.82 Bn | 191.22 Bn | 7.24 Bn | 11.69 Bn |
| 8 | Gilead Sciences | 190.63 Bn | 164.82 Bn | 6.22 Bn | 11.83 Bn |
| 9 | Pfizer | 169.35 Bn | 115.99 Bn | 10.94 Bn | 85.49 Bn |
| 10 | SAB Biotherapeutics | 228.89 Mn | -188.61 Mn | - | 214.79 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 214.79 Mn |
| Mar 31, 2026 | 227.25 Mn |
| Dec 31, 2025 | 151.50 Mn |
| Sep 30, 2025 | 165.07 Mn |
| Jun 30, 2025 | 12.02 Mn |
| Mar 31, 2025 | 21.41 Mn |
| Dec 31, 2024 | 25.97 Mn |
| Sep 30, 2024 | 36.90 Mn |
| Jun 30, 2024 | 46.12 Mn |
| Mar 31, 2024 | 52.82 Mn |
| Dec 31, 2023 | 57.30 Mn |
| Sep 30, 2023 | 15.26 Mn |
| Jun 30, 2023 | 19.72 Mn |
| Mar 31, 2023 | 24.40 Mn |
| Dec 31, 2022 | 31.06 Mn |
| Sep 30, 2022 | 30.62 Mn |
| Jun 30, 2022 | 37.12 Mn |
| Mar 31, 2022 | 41.26 Mn |
| Dec 31, 2021 | 38.55 Mn |
| Sep 30, 2021 | 35.08 Mn |
API Access
SAB Biotherapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=SABS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "SABS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=SABS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();